Procter & Gamble (NYSE:PG) and Colgate-Palmolive (NYSE:CL) reported quarterly earnings in January, placing two of consumer staples' most decorated dividend payers in sharp contrast. Procter & Gamble carries 69 consecutive years of dividend increases, while Colgate has notched 63 straight years. Both navigate tariffs, sluggish volume, and cautious consumer spending.
Procter & Gamble (PG) reported flat organic sales in Q2 FY2026 with 1% pricing offset by 1% volume decline, while facing $400M in annual tariff costs and 6.53% operating income decline despite 1.5% revenue growth. Colgate-Palmolive (CL) posted stronger Q4 2025 with 2.2% organic sales growth and $5.23B revenue beating estimates by 2.04%, though a $919M Filorga goodwill impairment resulted in negative $0.05 GAAP EPS. Procter & Gamble pursues large-scale restructuring with 7,000 overhead cuts and 26.16% capex growth to offset tariff drag and stabilize margins, while Colgate targets faster execution through AI analytics and its 2030 strategy, creating divergent risk-reward profiles for long-term dividend investors.
The analyst who called NVIDIA in 2010 just named his top 10 AI stocks. Procter & Gamble's Q2 FY2026 showed a business holding ground rather than accelerating. Organic sales came in flat, with 1% pricing offset by a 1% unit volume decline.
Beauty led with 5% organic growth, and Health Care matched that pace. Baby, Feminine & Family Care weakened, where organic sales fell 4%, with Family Care down double digits. READ: The analyst who called NVIDIA in 2010 just named his top 10 AI stocks Colgate's Q4 2025 told a livelier top-line story.
Revenue rose 5.8% year-over-year to $5.23 billion, beating estimates by 2.04%. Organic sales grew 2.2%, with 3.1% foreign exchange tailwind amplifying the headline. Hill's Pet Nutrition contributed $1.20 billion, up 4.9%, and Africa/Eurasia surged 10.3% organically.
North America slipped 1.8% organically. The quarter carried a painful footnote: a $919 million goodwill impairment on the Filorga skin health business, driven by weak China performance, pushing GAAP EPS to -$0.05. Procter & Gamble is restructuring at scale.
Extract — continue reading at the source.
